Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain

Health Economics Review

Volumn 3, Issue 1, 2013, Pages 1-11

  Blasco, Antonio J ^a   Lázaro, Pablo ^a   Caballero, Teresa ^b   Guilarte, Mar ^c  

^a Advanced Techniques in Health Services Research (TAISS)   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

C1 INH; Economic evaluation; Hereditary angioedema; Icatibant

Indexed keywords

ICATIBANT;

ANGIONEUROTIC EDEMA; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG ADMINISTRATION; DRUG SELF ADMINISTRATION; HEALTH CARE COST; HEALTH PROFESSIONAL ADMINISTRATION; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PRODUCTIVITY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SPAIN;

EID: 84971333776     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-3-2     Document Type: Article

References (41)

1. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fáy K, Fekete B, Fischer B, Fontana L, Füst G, Giacomelli R, Gröner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmár L, Kaposi PN, Karádi I, Kitzinger A, Kollár T, et al: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004, 114(Suppl 3):S51-S131.
2. Caballero T, Baeza M, Cabañas R, Campos A, Cimbollek S, Gomez-Traseira C, González-Quevedo T, Guilarte M, Jurado-Palomo GJ, Larco JI, López-Serrano MC, López-Trascasa M, Marcos C, Muñoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A, Spanish Study Group on Bradykinin-Induced Angioedema: Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Invest Allergol Clin Immunol 2011, 21:333-347.
3. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W: Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000, 75:349-354.
4. Bork K, Barnstedt SE: Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 2003, 134:1088-1094.
5. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W: Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol 2007, 119:1497-1503.
6. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, et al: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363:532-541.
7. th.
8. Aberer W, Toubi E: Safety, Tolerability and Efficacy of Self-Administered Icatibant for Acute Attacks of Hereditary Angioedema (P337). Boston, Massachusetts (USA): The American College of Allergy, Asthma and Immunology. 2011 Annual Scientific Meeting; 2011.
9. th.
10. Boccon-Gibod I, Bouillet L, On behalf of the EASSI Study Investigators: Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012, 168:303-307.
11. Floccard B, Hautin E, Bouillet L, Coppere B, Allaouchiche B: An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. Core Evidence 2012, 7:105-114.
12. th.
13. th.
14. ORDER of 14 October 2005, which are priced public health services provided by centres under the Andalusian Public Health System. Official Gazette of the Autonomous Community of Andalusia 2005, 210.
15. ORDER of the Minister of Health and Consumer, of 11 September 2008, amending the Order of the Minister for Health and Consumers of 22 December 2006 laying down the public prices to be applied by health centres in the public network of the Balearic Islands by the provision of health services when there are third parties required to pay or users without the right to health care of Social Security. Official Gazette of the Balearic Islands 2008, 131.
16. LAW 12/2009 of 23 December on Fiscal, Administrative and Financial Management, and Organization of the Valencia Government. Official Gazette of the Autonomous Community of Valencia 2009, 6175.
17. ORDER 629/2009 of 31 August, fixing public prices for the provision of services and health activities of the network of centres of the Community of Madrid. Official Gazette of the Community of Madrid 2009, 215.
18. ORDER of 17 May 2007, of the Ministry of Health, which creates public prices applied by the Health Service of Murcia, for the provision of health services and the supply of blood products. Official Gazette of the Region of Murcia 2007, 129.
19. RESOLUTION, 1687/2010 of 24 August, of the Managing Director of Navarra Health Service, which amends Resolution 882/2010 of 3 May, of the Managing Director of Navarra Health Service for updating the fees by the provision of services in centres and care establishments of Navarra Health Service. Official Gazette of Navarre 2010, 115.
20. AGREEMENT of 13 December 2007, the Board of Directors of the Public Entity Osakidetza Basque Health Service, for approving the tariffs for the provision of health and educational services to third parties required to pay to during 2008. Official Gazette of Basque Country 2008, 12.
21. RESOLUTION of 16 June 2009, of the National Institute of Health Management, on price review to be applied by the health centres in the Autonomous Cities of Ceuta and Melilla by the medical care in the cases whose amount have to be claimed to third parties required to pay or users without the right to health care of Social Security, as well as services provided by the National Dosimetry Centre and reproduction of documents in the library of the managing body. Government Gazette 2009, 150.
22. RESOLUTION of 2 April 2004, of the Directorate Management of Aragon Health Service on revision of tariffs to apply by the provision of health services to third parties required to pay or to users without the right to health care of Social Security in the Community Aragon. Official Gazette of Aragon 2004, 46.
23. DECREE 34/2006 of 19 April, by which set prices by the provision of services and activities of health by centres under the Health Service of the Principality of Asturias. Official Gazette of the Principality of Asturias 2006, 105.
24. DECREE 81/2009 of 16 June, establishing the public prices of health services provided by the Canary Islands Health Service and fixing their amount. Official Gazette of the Canary Islands 2009, 123.
25. ORDER SAN/8/2007 of 4 April, which fixing the amounts of the public prices of health services provided by the Cantabrian Health Service. Official Gazette of Cantabria 2008, 74.
26. RESOLUTION of 6 April 2010, the Directorate Management, about prices to apply by their health centres to third parties required to pay or users without the right to health care [2010/6830]. Official Gazette of Castilla-La Mancha 2010, 79.
27. DECREE 25/2010 of 17 June, updating of public prices are by acts of care and health services provided by the Regional Health Management of Castile and Leon. Official Gazette of Castile and Leon 2010,119.
28. RESOLUTION SLT/383/2009 of 21 January on the review of public fees for health services provided by the Catalan Health Institute. Official Gazette of Government of Catalonia 2009, 5325.
29. DECREE 21/2009 of 13 February, changing the amounts of public prices for health services from the Extremadura Health Service established in Decree 272/2005 of 27 December, which down and regulate public prices for health services from the Extremadura Health Service. Official Gazette of Extremadura 2009, 34.
30. DECREE 160/2010 of 23 September, establishing fees for health services provided in the centres under the Galician Health Service and public health foundations. Official Gazette ofGalicia 2010, 188.
31. RESOLUTION No. 143 of 4 May 2010, of the Minister of Health by providing for the publication of the charges for health services provided to individuals in the centres of the Rioja Health Service. Official Gazette of the Rioja 2010,57.
32. th.
33. th.
34. th.
35. th.
36. Maurer M, Aberer W, Bouillet L, Caballero T, Fabient V, Kanny G, Kaplan A, Longhurst H, Zanichelli A, on behalf of IOS Investigators: Hereditary Angioedema Attacks Resolve Faster and are Shorter After Early Icatibant Treatment. Plos One 2013, 8(2):E53773. doi:10.1371/journal.pone.0053773
37. Bygum A, Andersen KE, Mikkelsen CS: Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009, 19:147-151
38. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B: HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010,6:22
39. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, et al: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010, 6:24.
40. Caballero T, Baeza M, Cabañas R, Campos A, Cimbollek S, Gomez-Traseira C, González-Quevedo T, Guilarte M, Jurado-Palomo GJ, Larco JI, López-Serrano MC, López-Trascasa M, Marcos C, Muñoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A, Spanish Study Group on Bradykinin-Induced Angioedema: Consensus Statement on the Diagnosis, Management And Treatment of Angioedema Mediated by Bradykinin. Part II. Treatment, Follow-Up, and Special Situations. J Investig Allergol Clin Immunol 2011, 21422-441
41. Cicardi M, Bork K, Caballero T, Craig T, Li H, Longhurst H, Reshef A, Zuraw B, HAWK (Hereditary Angioedema International Working Group: Evidence-based recommendations for the therapeutic management of angioedema due to hereditary C1-Inhibitor deficiency. Consensus report of an International Working Group. Allergy 2012, 129:308-320